Record mula sa primary source
Decision-gradeTopline na resulta
Amgen: Naabot ng Phase 3 CROSSING trial ng TEZSPIRE ang mga co-primary endpoint sa EoE
Ang Phase 3 CROSSING trial ng TEZSPIRE sa eosinophilic esophagitis ay nakamit ang parehong co-primary endpoints (histologic remission at dysphagia symptom improvement) at lahat ng key secondary endpoints sa linggo 24, na may mga resulta na nagpatuloy hanggang sa linggo 52. Ang safety profile ay nanatiling pare-pareho sa mga aprubadong indikasyon. Ang buong resulta ay ibabahagi sa mga regulator at ipapakita sa isang paparating na medikal na pagpupulong.
Mahahalagang fact
- Na-file
- Ago 27, 2026, 06:00 AM
- Kaganapan
- Topline na resulta
- Direksyon
- Positibo
- Kumpanya
AMGNAmgen- Asset
- tezepelumab-ekko
- Pinagmulan
- Press release ng kumpanya
- Kumpiyansa
- May source
Sipi mula sa source
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS News provided by Amgen Aug 27, 2026, 02:00 ET Share this article Share to X Share this article Share to X Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52 Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of TEZSPIRE THOUSAND OAKS, Calif. , Aug. 27, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca today announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE ® (tezepelumab-